MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
4.870
+0.090
+1.88%
After Hours: 4.870 0 0.00% 19:34 08/12 EDT
OPEN
4.840
PREV CLOSE
4.780
HIGH
5.08
LOW
4.700
VOLUME
1.63M
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
3.990
MARKET CAP
382.40M
P/E (TTM)
-3.3503
1D
5D
1M
3M
1Y
5Y
1D
Lexeo Advances LX2006 Pivotal Program; SUNRISE-FA 2 Data Expected In 2H27
NASDAQ · 19h ago
Lexeo Therapeutics advances gene therapy and gains RMAT status
TipRanks · 20h ago
Lexeo Therapeutics GAAP EPS of -$0.30 misses by $0.01
Seeking Alpha · 20h ago
Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate
Benzinga · 20h ago
Press Release: Lexeo Therapeutics Reports Second -2-
Dow Jones · 20h ago
Press Release: Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Dow Jones · 20h ago
Weekly Report: what happened at LXEO last week (0803-0807)?
Weekly Report · 2d ago
Lexeo Therapeutics management to meet with Cantor
TipRanks · 6d ago
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.